Seattle Genetics, Inc.

Bothell, WA 98021

Market Performance

NASDAQ: SGEN
Market Cap $8.77 Billion
52 Week High $75.36
52 Week Low $45.31

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $544K
First Award Date 01/24/00
Most Recent Award Date 09/01/05

Key Personnel

Last Name Name Awards Contact
Senter Peter D Senter 2
Kline Toni B. Kline 1
Carter Paul J. Carter 1

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 08/31/06

DESCRIPTION (provided by applicant): Antibodies are the most rapidly expanding class of drugs to treat human disease, including cancer. However, current antibody therapies in oncology are seldom, if ever, curative. Thus there remains a need to improve the response rate and duration for anti-cancer antibodies. Conjugation to cytotoxic drugs is on...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/16/02 - 11/30/03

DESCRIPTION (provided by applicant): The proteolytic activity of matrix metalloproteases (MMPs)-2 and -9 is highly localized to the outer surfaces of invasive tumors. The goal of this project is to synthesize and evaluate prodrugs that are selectively cleaved by MMP-2 and -9 at the tumor site. Using both direct attachment and cleavable linkers,...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 08/31/02

Phase I and II clinical trials with BR96-doxorubicin, an immunoconjugate that recognizes receptors on human carcinomas, have demonstrated that the monoclonal antibody component, BR96, is capable of safely delivering active doxorubicin to tumor masses, albeit at concentrations that are sub-optimal. We propose to construct and test significantly i...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/24/00 - 12/31/00

CPT-11 is a clinically approved anticancer agent. When administered in people, CPT-11 acts as a prodrug, and is converted by carboxylesterases to the active drug, SN-38, an agent with approximately 1 ,000 times more cytotoxic activity. Since only 2 - 5% of the injected CPT-11 is converted to SN-38, a great opportunity exists to improve its activ...